Methods: A total of 260 children (140 patients with asthma and 120 control subjects) were enrolled in this study. PTX3 levels were measured in sputum supernatants with ELISA. We performed spirometrys and methacholine challenge tests while measuring total eosinophil count, and serum levels of total IgE and ECP in all children.
Results: Sputum PTX3 concentration was significantly higher in children with asthma (mean ± SE, 1094.55 ± 224.65 pg/mL) than control subjects (mean ± SE, 177.36 ± 30.00 pg/mL, p < 0.001). Positive significant correlations were found between sputum PTX3 and bronchodilator response (r = 0.25, p = 0.013). Sputum PTX3 levels negatively correlated with FEV1 (r = -0.30, p = 0.001), FEV1/FVC (r = -0.27, p = 0.002), FEF25-75 (r = -0.392, p < 0.001). Sputum PTX3 levels also showed significant negative correlation with post- bronchodilator (BD) FEV1 (r = -0.25, p < 0.001) and post-BD FEV1/FVC (r = -0.25, p < 0.001).
Conclusions: Our results could support that PTX3 is involved in the pathogenesis of asthmatic airway. Sputum PTX3 would be a supportive biomarker reflecting asthmatic airway inflammation and remodeling in childhood asthma.